Aravive was founded with the mission to develop novel therapeutics to improve the health and extend the lives of patients with cancer and fibrotic diseases.

Our science is driven by an understanding of the central role played by GAS6/AXL signaling in cell migration and invasion. Our drug candidates are designed to block this pathway by intercepting the binding of AXL to its sole ligand, GAS6, by means of a novel ultra-high affinity AXL decoy receptor, AVB-500.